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ABSTRACT 
Liquid Avonex® (Interferon beta-1 a) manufactured by Biogen, Inc. is 
indicated for the treatment of relapsing forms of multiple sclerosis (MS) to slow the 
accumulation of physical disability and decrease the frequency of clinical 
exacerbations. The recommended dosage of A vonex® for the treatment of relapsing 
forms of MS is 30 µg injected intramuscularly once a week. Several complications 
have been reported following intramuscular (IM) injections, of which pain at the 
injection site is the most common. Though factors such as site of injection, injection 
volume, concentration and nature of the drug may affect the reception of pain, one 
factor which has not apparently been given any attention in the published literature is 
the ease of injectability of the syringe, which is the amount of force required to expel 
the drug from the syringe. This factor can be expected to have a substantial effect on 
the discomfort experienced by patients and on the completeness of the injection (i.e. 
the percentage of dose delivered). An evaluation of the published literature by the 
author of this thesis has failed to reveal any publications dealing with the role of 
injectability as a measure for easing the pain on injection. There is a need for some 
objective, quantitative method for measuring the ease of injectability such as may be 
provided by use of the Instron Series 5500. 
The purpose of this study was to perform compressive studies on the 
intramuscular injection, Liquid Avonex® staked and luer-slip pre-filled syringes 
using the Instron Series 5500. The Instrument generates an expulsion force profile 
from which the force required for the initial movement of the plunger into the 
syrmge (breakout force) was calculated. An ideal synnge with good ease of 
injectability will have minimum breakout force and a smooth expulsion profile. Thus 
by studying the various factors affecting the expulsion force profile, the ease of 
injectability of syringes was quantified. The various factors studied were age and 
viscosity of silicone oil, storage temperature, addition of surfactant and the speed of 
expulsion. The viscosity of the silicone oil and the method of siliconization were 
found to be critical factors defining the expulsion force profile. The 1000 cSt silicone 
oil was found to give better ease of injectability than the 12,500 cSt silicone oil. 
Increase of storage temperature, addition of surfactant and increase of expulsion 
speed did not have any substantial effect on the expulsion force profile of the 
syrmge. 
Pain on IM injection is also related to the mechanical properties of the 
needle insertion, which include the maximum force required to penetrate the muscle 
and the penetration profile of the needle into the muscle. Needle penetration studies 
were conducted to examine the injection profiles of staked and non-staked needle 
sharps using a model intramuscular injection pad. The results showed that non-
staked needles need lesser penetration force and show linear penetration profile in 
comparison with staked needles and hence cause less pain on injection. 
In conclusion, the results reported in this study clearly indicate that 
compressive studies using the Instron Series 5500 are an effective and convenient 
way to quantify the ease of injectability of syringes. 
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( PREFACE 
This thesis has been prepared in the format of the manuscript plan in 
accordance to section 11-3 of the Graduate Manual at the University of Rhode 
Island. 
The thesis has been divided into three sections. Section I contains a brief 
introduction on intramuscular (IM) injections, the complications following IM 
injections especially the pain on injection, importance of injectability studies to ease 
the pain on injection and use of the Instron Series 5500 to evaluate the ease of 
injectability of syringes. This is followed by the objectives of the study. Section II 
forms the central part of the thesis and is composed of a manuscript written in the 
format prescribed by the scientific journal, Drug Development and Industrial 
Pharmacy to which the manuscript will be submitted for publication. It also includes 
a summary of the entire thesis and some suggestions for future work. Section III 
contains appendices that include graphs and tables useful for clear understanding of 
the results described in the manuscript. A report "Statement for the use of I 000 cSt 
silicone oil instead of 12,500 cSt silicone oiI'' by Vetter Pharma, a contract 
manufacturer of Biogen, Inc. has been included in appendix C. This document 
provided the basis for testing the effect of viscosity of silicone oil on the expulsion 
force profile of Liquid Avonex® pre-filled syringes. The bibliography for the entire 
thesis follows the Section III. 
v 
( It was not possible to include all the graphs related to the study in the 
manuscript due to adherence to the journal requirements. Hence some representative 
graphs have been included in the manuscript. For ease of understanding, some 
graphs have been included in both the manuscript as well as in the appendix. 
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( SECTION I 
INTRODUCTION 
1. Routes of Drug Administration 
Drug substances are normally administered as part of a formulation in 
association with one or more pharmaceutical adjuvants ( excipients) that serve 
various pharmaceutical functions. The selective use of these pharmaceutical 
excipients results in dosage forms ( 1 ). Drug dosage forms are designed based on the 
nature of the disease, the intended route of administration, the size of the dose, the 
anatomic and physiologic characteristics of the administration site and the interaction 
of the drug and dosage form at the administration site (2). Amongst the various 
routes for administration of drugs, the oral route is the most preferred route by the 
patients. The oral route is a natural, uncomplicated, convenient and safe means for 
administering drugs. The major disadvantage of this route is the potential problem of 
poor bioavailability (the rate and extent of active drug that reaches the systemic 
circulation) due to incomplete absorption. Drugs when taken orally and swallowed 
are normally absorbed from the small intestine into the hepatic portal vein and are 
transported to the liver. During this first pass, a portion of the drug substance may be 
metabolized by the liver enzymes before the drug enters the hepatic vein which 
drains into the heart and thus reaches systemic circulation. This is known as first-
pass effect (1). Slow drug response and degradation of certain drugs by the stomach 
acid or gastrointestinal enzymes are other disadvantages of the oral route. Generally 
drugs with high molecular weights are not absorbed well when given orally. Barriers 
to oral delivery of macromolecules include low pH of the stomach, enzymatic 
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degradation and limiting diffusivity through the gastrointestinal epithelium (3). An 
example is Insulin, which is administered parenterally due to the destruction of the 
hormonal protein substance by the proteolytic enzymes of the gastrointestinal tract 
(1 ). 
The term parenteral means next to or beside the enteral. Enteral refers to 
the alimentary tract, hence parenteral means sites that are outside of or beside the 
alimentary tract. The three primary routes of parenteral administration are 
subcutaneous (SC or SQ), intramuscular (IM), and intravenous (IV) although there 
are other less common routes such as intradermal, intracardiac, intraarticular, 
intrathecal. The nature of the drug determines the particular route of administration 
to be employed (1). Drugs destroyed or inactivated in the gastrointestinal tract or too 
poorly absorbed to provide satisfactory response are administered parenterally. The 
parenteral route is also preferred when a rapid and predictable drug response is 
desired. However it is the most hazardous way to administer a drug. When done 
incorrectly, the patient's nerves, bones, tissues or blood vessels could be damaged 
(4). 
Intravenous administration provides the most rapid onset of action of 
any parenteral route because there is no barrier to absorption. IV injections are 
usually given into the veins of the forearm. Drugs that are too irritating for IM or SC 
administration are given by this route. 
2 
The SC route of administration of drugs involves their injection through 
the layers of the skin into the loose subcutaneous tissues of the upper arm, the 
anterior surface of the thigh, or the lower portion of the abdomen. Absorption after 
SC administration is generally more rapid and predictable than after oral 
administration. Heparin and Insulin are the most important drugs routinely 
administered by this route. Drugs that are administered by this route must be potent 
in small concentrations since only a small volume can be injected. 
2. Intramuscular Injections 
IM injections are made into the striated muscle fibres that are under the 
subcutaneous layer of skin. The principle sites of injection are the gluteal (buttocks), 
deltoid (upper arm) and vastus lateralis (thigh) muscles. The onset of action is 
typically longer than with IV administration, but shorter than with SC administration. 
IM injections generally result in lower but more sustained blood concentrations than 
after IV administration. This is because IM injections require an absorption step 
which delays the time taken to achieve peak concentrations. When the formulation is 
injected, a "depot" forms inside the muscle tissue, which acts as a repository for the 
drug. The absorption rate from this depot depends on various physiological as well 
as formulation factors. Drugs which are irritating to subcutaneous tissue are often 
administered intramuscularly. Also, larger volumes (2-5 ml) may be injected 
intramuscularly than subcutaneously (2 ml) (1). Patients generally experience more 
pain via IM administration compared to IV and SC administration. 
3 
( 3. IM Injection Sites 
The effect of a medication can be enhanced or diminished depending on 
the site of injection. Selection ofIM injection site is influenced by age of the patient, 
the nature and amount of medication to be injected and the general consideration of 
the patient. Damaged or scarred tissue, poor muscle mass or tone and accessibility or 
mobility factors may contraindicate a particular site (5). There are five injection sites 
that are commonly used for the administration ofIM injections. 
3.1 The deltoid site 
Drugs are absorbed rapidly from this site. However, the small area of 
the site limits the number and volume of injections which can be given. The site is 
close to both the radial nerve and the deep brachia! artery. Hence there is potential 
for patient injury. It is used commonly for tetanus toxoid boosters (4, 5). 
3.2 The dorsogluteal site 
The presence of major nerves such as sciatic nerve and blood vessels 
such as superior gluteal artery, the relatively slow uptake of medication from this site 
compared with others and the thick layer of adipose tissue commonly associated with 
it, makes this site problematic. However, the large area of the site makes it suitable 
for multiple injections over a period of time (4, 5). 
4 
3.3 The rectos femoris site 
Uptake of drugs from this site is slower than that of the deltoid, but 
faster than from the gluteal. This site is used when other sites are contraindicated or 
when patients have to self-administer the medication. The main disadvantage is that 
injections into this area may cause considerable discomfort (5). 
3.4 The vastrus lateralis site 
This site is free of blood vessels, is well developed in adults and is easily 
accessible. Since the muscle tissue is well developed, there is less likelihood of 
injury. But the area has a number of small nerve endings, which causes pain after the 
injection ( 4, 5). 
3.5 The ventrogluteal site 
This site has gained attraction recently and is considered by some to be 
the site of choice for IM injections. It consists of thick gluteal muscle, is free of 
penetrating nerves and blood vessels, and has a narrower layer of fat as compared to 
the dorsogluteal site (6). It is suitable for immobilized patients whose dorsogluteal 
muscles may be atrophying (5). 
4. Complications Following IM Injections 
The complications which have followed IM injections are contractures, 
palsy, local irritation, pain, infection, arterial punctures, abscess and cyst formation, 
necrosis, slough of skin, scar formation, intravascular injections, periostitis and 
5 
peripheral nerve injuries with consequent neurologic deficits (7). There are several 
factors that contribute to these complications. 
4.1 The injection site 
Complications following IM injections have been reported to occur 
with all injection sites except the ventrogluteal site. The less frequent use of this site 
may be the cause of the apparent lack of complications for this site (5). Presence of 
important nerves and vascular structures, thickness of the SQ fat are factors to be 
considered during the selection of an injection site. 
4.2 The injectate 
The concentration and type of the injectate plays an important role in 
muscle tissue response. Drugs like cephalothin sodium, tetracycline and digoxin 
cause injection site complications with a relatively high frequency. Some antibiotics 
like procaine penicillin and oxytetracycline cause least extensive reactions at the 
injection site (7). The ability of the muscle to accommodate the injectate is another 
consideration for muscle complications (8). 
4.3 Frequency of injection 
Multiple injections into the same site increase the risk of complications. 
Any drug when repeatedly injected causes fibrosis of the muscle and subsequent 
joint contracture. Hence it is advisable to change the injection site in case of chronic 
treatments. 
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4.4 Patient 
The SQ tissue of the gluteal muscle varies from 9 cm in obese to 1 cm in 
old and emaciated individuals. This causes variability in the depth of musculature. 
Hence erroneous deposition of the drug into the SQ tissue is quite common. Disease 
conditions such as diabetes, ketoacidosis, malnutrition or hypotension have been 
related to SQ localized mucormycosis infection (8). 
4.5 Needle 
The length of the needle is decided based on the site of the injection and 
the age of the patient (9). A 1 Yi-inch needle is used for a normal adult; one-inch 
needles are used for thin adults and %-inch for young children and infants. Longer (2 
- 2Yz-inch) needles are used for obese patients (4). Occurrence of pain is found to be 
significantly related to the size of the needle and the velocity of insertion ( 10). 
4.6 Method of injection 
There are two methods for administering IM injections - the Standard 
method and the Z-track method. The standard method involves spreading the skin 
above the injection site between the fingers of the practitioner's non-dominant hand. 
This method is believed to increase the risk of medication leaking into the needle 
track. The Z-track technique involves pulling the skin either downward or laterally to 
about 1-1.5 inches before injection using the non dominant hand (5). The skin and 
the subcutaneous tissue are displaced before the injection and the valve action of the 
skin and superficial tissue is used to prevent leakage. The displaced tissue returns to 
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its normal position and overlaps the needle track once the injection is completed (9). 
This procedure is shown to decrease leakage of medication into the SQ tissue, thus 
causing less pain and discomfort for the patient (11). 
4.7 Air Bubble Technique 
A topic that engenders heated debate among clinicians is the use of an 
air bubble in the syringe. In the days of glass syringes, an air bubble of 
approximately 0.2 ml was necessary to account for dead space in the needle hub and 
to ensure accuracy when drawing up the medication. However, modem disposable 
syringes are calibrated to deliver an accurate dose of medication, taking into account 
the volume of medication in the hub (9) . An air bubble in the syringe is known to 
affect the dosage of the medication by a factor of 5% to 100% (12, 13, and 14). In a 
pre-filled syringe, the dosage is accurately provided by the manufacturer and an air 
bubble is not needed. Thus drawing up an air bubble is an outdated, unnecessary and 
potentially dangerous procedure for the patients and should be eliminated from IM 
injection procedure (9, 11). 
Administering an IM injection is a common, yet complex technique that 
requires skill and knowledge on part of the person administering the injection. There 
are numerous reports in the literature of patient complications due to improper 
administration of IM injections (9). Inserting and removing the needle too slowly 
may distort the epidermis thereby increasing tissue trauma and pain. However, the 
medication must be injected slowly over several seconds. Injecting the medication 
8 
rapidly in the hope of minimizing the patient's reaction, results in the drug being 
injected throughout the procedure from the time the skin is punctured and continuing 
into the deep tissues. This can cause deposition of drug in the SQ fat (7). 
5. Pain on Injection 
Pain at the injection site is the most commonly reported complication 
following IM injection. Quantification of pain on injection has been done with the 
use of pain questionnaires. Two commonly used pain questionnaires are the McGill 
Present Pain Intesity (PPI) and the Brief Pain Inventory (BPI). The PPI measures the 
pain on a scale of 0 (no pain) to 5 (excruciating pain) and the BPI measures pain on a 
scale of 0 (no pain) to 10 (pain as bad as you can imagine). It has been found that 
both the instruments have sufficient discriminative validity to distinguish between 
different levels of injection-site pain (15). Another commonly used scale to study the 
pain intensity is the visual analogue scale (VAS) (16, 17, 18). The VAS is a simple 
scale consisting of a 10 cm line anchored at one end by a label such as "No Pain" 
and at the other end "Worst Possible Pain". The patient marks a spot on the line for 
the pain intensity and it is measured. 
Though factors such as site of injection, injection volume, concentration 
and nature of the drug may affect the reception of pain, one factor, which has not 
apparently been given any attention in the published literature, is the ease of 
injectability of the syringe, which is the amount of force required to expel the drug 
from the syringe. This factor can be expected to have a significant effect on the 
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discomfort experienced by patients and on the completeness of the injection (i.e. the 
percentage of dose delivered). An evaluation of the published literature by the author 
of this paper has failed to reveal any publications dealing with the role of 
injectability as a measure for easing the pain on injection. There is a need for some 
objective, quantitative method for measuring the ease of injectability such as may be 
provided by the Instron Series 5500. 
6. Instron Series 5500 
The Instron Corporation manufactures instruments to test torsion, 
compression, flexure, peel, sheer, friction, hardness, fatigue, fracture, structure and 
several other mechanical properties. The Instron Series 5500 allows test samples to 
be subjected to forces either compressive (crushing), tensile (pulling), deflection 
(bending), or torsion (twisting) and measures the effect of forces on the physical 
properties of the material like the strength, brittleness and ductility. This equipment 
is composed of a load frame which is designed for tension, compression and reverse 
stress testing. Load frames are engineered for precision, speed, accuracy, safety and 
reliability. The load frame specifically designed for performing compressive studies 
on pre-filled syringes is the Model 5542. The testing capacity for Model 5542 is 
defined as 500 N/112 lb with a speed of 40 in/min. The control electronics of the 
Model 5542 feature 200 Hz data collection which enables advanced real-time 
control. They can control the frame using any combination of load, strain or speed 
rates. Merlin is the software that controls the Instron 5500 testing systems for test 
setup, test control, data collection, result generation and report preparation. The 
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software features a graphical user interface fully implemented in windows®. The 
flexibility of the software allows changes to be made to testing requirements. 
Merlin's built-in test control and calculation tools allows user to create customized 
tests without modifying the software macros ( 19). 
The Instrument generates an expulsion force profile from which the 
force required for the initial movement of the plunger into the syringe (breakout 
force) can be calculated. An ideal syringe with good ease of injectability will have 
minimum breakout force and a smooth expulsion profile. Thus by studying the 
various factors affecting the expulsion force profile, the ease of injectability of 
syringes can be improved. 
7. Avonex® and MS 
The intramuscular injection, the ease of injectability of which has been 
evaluated in this study, is Liquid Avonex® (Interferon beta-la). Interferon beta-la is 
a 166 amino acid glycoprotein with a predicted molecular weight of approximately 
22,500 daltons. A vonex® is manufactured by recombinant DNA technology 
(Biogen, Inc.) and is indicated for the treatment of relapsing forms of multiple 
sclerosis (MS) to slow the accumulation of physical disability and decrease the 
frequency of clinical exacerbations. MS is an inflammatory, autoimmune, 
demyelinating disease of the central nervous system. It involves decreased nerve 
function associated with formation of scars on the surface of nerve cells. It generally 
strikes the early adult age, but persists for a period of 30 years. The symptoms 
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include numbness, impaired vision, loss of balance, weakness, bladder dysfunction 
and other physiological changes (20). The damage to myelin in MS is believed to be 
due to an abnormal response of the body's immune system. Avonex® is not a cure 
for MS; it only helps in slowing the progression of the disease. The current 
commercial formulation of A vonex® is in the form of a lyophilized powder in a 
single-use vial and is reconstituted with 1.1 ml of diluent (Sterile Water for Injection, 
USP). 
The recommended dosage for the treatment of relapsing forms of MS is 
30 mcg injected intramuscularly once a week. It is intended for use under the 
guidance of a physician. However, many patients self-inject Avonex® after receiving 
proper training in intramuscular injections. For the treatment of a chronic disease 
such as MS, it is highly desirable to have a mode of injection with reliability and 
little discomfort. In order to avoid the lengthy process of preparing the injection, a 
second-generation formulation of A vonex® is being developed by Biogen, Inc. to be 
supplied in the form of a liquid in a pre-filled syringe. Further research is being done 
for incorporation of the Liquid Avonex® pre-filled syringe into an autoinjector. 
An autoinjector is a spring-driven injection device, which penetrates the 
skin and injects the drug automatically. It is a hand-held device that completely hides 
the needle through the injection process, making administration more manageable. It 
allows patients to self-administer injections with great ease. Compressive studies 
using Instron Series 5500 can play a role in defining the device variables for the 
12 
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autoinjector. The spring tension of the autoinjector is set based on the breakout force 
of the syringes. 
13 
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OBJECTIVES 
The objectives of this study have been listed below: 
1. To review the published literature for data pertinent to the formulation of 
intramuscular injection with particular reference to factors which may affect 
ease of injectability. 
2. Perform compressive studies on Liquid Avonex® pre-filled luer-slip and 
staked needle syringes using the Instron Series 5500. 
3. Generate the expulsion force profile and calculate the maximum force at 
breakout, 10 mm and 15 mm extension. 
4. Study the effect of various factors on the breakout force and the expulsion 
force profile of the pre-filled syringes. 
5. Perform needle penetration studies to compare the injection profiles of staked 
and non-staked needle sharps using a model intramuscular injection pad. 
6. To evaluate the potential of Instron type equipment for the quantification of 
ease of injectability 
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Abstract 
SECTION II 
MANUSCRIPT 
QUANTIFICATION OF INJECTABILITY OF A NEW 
SELF-ADMINISTERED INTRAMUSCULAR INJECTION 
This paper reports compressive studies of the intramuscular injection, 
Liquid Avonex® staked and luer-slip pre-filled syringes. The ease of injectability of 
the syringes has been quantified. Compressive studies have been performed using the 
Instron Series 5500. The effects of various factors such as age and viscosity of 
silicone oil, storage temperature, addition of surfactant and effect of expulsion speed 
on the expulsion force profiles were determined. The viscosity of the silicone oil and 
the method of siliconization were found to be critical factors defining the expulsion 
force profile. The 1000 cSt silicone oil was found to give good ease of injectability. 
Also needle penetration studies were conducted to examine the injection profiles of 
staked and non staked needle sharps using a model intramuscular injection pad. The 
results showed that non-staked needles showed a better penetration profile and 
minimized the pain on injection. 
Keywords: Injectability, Instron, expulsion force profile, siliconization, luer-slip, 
staked needles. 
1. INTRODUCTION 
Avonex® (Interferon beta-1 a) manufactured by Biogen, Inc. is 
indicated for the treatment of relapsing forms of Multiple Sclerosis and is used at a 
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dose of 30 mcg injected intramuscularly once a week. A vonex® is a recombinant, 
fully glycosylated Interferon beta- I-a that is produced by Chinese hamster cells and 
is identical to native human Interferon-beta (1). The current commercial formulation 
of Avonex® is in the form of a lyophilized powder in a single-use vial and is 
reconstituted with 1.1 ml of diluent (Sterile Water for Injection, USP). A second-
generation liquid formulation of A vonex® is being developed by Biogen, Inc. to be 
given in the form of a pre-filled syringe. In addition to pre-filled syringes, 
autoinjectors are in development for the delivery of Avonex®. 
Administration of intramuscular injections can cause discomfort, and in 
some instances moderately severe pain to the patients. Though factors such as 
injection volume, site of injection, nature of the drug and muscle tone may play roles 
in defining the chances of such problems, one factor which has not apparently been 
given any attention in the published literature is the ease of injectability of the 
syringe, which is the amount of force required to expel the drug from the syringe. 
This parameter may well be expected to have a substantial effect on patient 
discomfort and even possibly the completeness of the injection (i.e. the percentage of 
dose delivered). Thus ease of injectability may modify the safety and efficacy of a 
parenteral dosage form. The increase in licit self-administration of parenterals makes 
an investigation of this topic especially timely. 
In the present study, compressive studies have been performed on 
Liquid Avonex® pre-filled luer-slip and staked needle syringes using the Instron 
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Series 5500. The Instron allows test materials to be subjected to forces either 
compressive (crushing), tensile (pulling), deflection (bending), or torsion (twisting) 
and measures the effect of forces on the physical properties of the material like the 
strength, brittleness and ductility. The Instrument generates an expulsion force 
profile from which the force required for the initial movement of the plunger into the 
syringe (breakout force) is calculated. The breakout force of a pre-filled syringe is 
regarded an important factor for the development of the device variables for the auto-
injector. The spring tension for an auto-injector is set based on the breakout force 
and the force at the end of the stroke of a pre-filled syringe. The effects of various 
factors on the expulsion force profile of Liquid A vonex® were determined. From the 
nature of the expulsion force profile, the ease of injectability of the pre-filled 
syringes was evaluated. 
2. MATERIALS 
Interferon beta-1 a (Liquid A vonex®)(Biogen, Inc., Cambridge, MA), 
Tween 20 (Polyoxyethylene Sorbitan Monolaurate)(Sigma Aldrich Co. St. Louis, 
MO), 0.22 µm STERIVEX-GV filter unit (Millipore Corporation, Bedford, MA), 
SCF 1 ml Long Luer CCT Syringe (Becton Dickinson™, Zp9843100, France, S.A.), 
Needle 23G l1/4 Precision Glides® (Becton Dickinson™, Franklin Lakes, NJ), 
Intramuscular injection pad (IMIP), Model # 00250 (Limbs and Things Ltd., Bristol, 
BS2 ORA, UK). 
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3.1 Instron Parameters/ Measurements 
The Instron model 5542 was used for the study, since it is a single 
column tester specifically designed for compressive testing on pre-filled syringes. 
Merlin software controls the Instron series for test-setup, test control, data collection, 
result generation and report preparation. The three main parameters to run a manual 
method using the Instron 5500 series are the Motion (speed) and Data (time and 
load). The Data (time) refers to the time interval for data collection and the Data 
(load) refers to the load needed for the data collection. Other parameters are the 
Extension and the Load. The load refers to the actual force that is applied by the 
instrument. The extension is set based on the distance traveled by the plunger into 
the syringe. Liquid Avonex® pre-filled syringes were subjected to different levels of 
speed, time and load and based on the nature of the expulsion force profile, i.e. the 
amount of noise produced and the number of data points collected, a suitable 
combination of the three parameters was achieved. The parameters set for the syringe 
expulsion studies were: Speed: 25 mm/min, Data (time): 150 msec, Data (load): 0.15 
N, Extension: 20 mm, Load: 30N. 
3.2 Force data 
A typical load vs. extension curve (expulsion force profile) of Liquid 
Avonex® pre-filled syringe is shown in figure 1. The curve characteristically 
demonstrates a peak, followed by a plateau. The rise in the curve at the end of the 
expulsion force profile occurs when the entire drug is expelled from the syringe. The 
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breakout force (load at which the first peak occurs) is the force required for the initial 
movement of the plunger into the syringe. The Fmax refers to the maximum force at 
any particular extension. The Fmax at 10 mm gives an indication of the amount of 
force required to expel the liquid when it is half way through the syringe. The Fmax 
at 20 mm refers to the state when the liquid nears the needle portion of the syringe. 
3.3 Intramuscular Injection Pad {IMIP) Parameters 
The injection penetration profiles of staked and non-staked needle sharps 
were studied by penetration into a model intramuscular injection pad (IMIP). 
Parameters were developed for the needle penetration studies similar to the syringe 
expulsion studies. The motion (speed) to inject both luer-slip and staked needles was 
50 mm/min. Penetration data was captured at a load of 0.15 N and a time of 150 
msec. A Precision Glides® 23 G needle was attached to the luer-slip syringes. The 
depth of penetration of the Precision Glides® 23 G needle and the staked needle into 
the IMIP was 32 mm. Hence the extension was set to - 35 mm. Thirty staked and 
luer-slip syringes were penetrated into the IMIP. 
3.4 Size Exclusion Chromatography (SEC) 
Distributions of intact protein, soluble aggregate and/or fragments of 
interferon beta-la were determined using SEC. A high-performance liquid 
chromatography (HPLC) system (Waters Alliance 2690) was used with a Superdex® 
G-75 column at a flow rate of 0.8 ml/min using 4.8A buffer as the mobile phase. 200 
µl of protein sample was injected into the column and detected by absorbance at 215 
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nm. Standards of known protein concentration were run as controls for each set of 
samples. Samples were run six times and the average value was used to determine 
the fraction of aggregated protein in the sample. The fractions of aggregate, intact 
protein and protein fragments were determined by assessing the relative peak areas 
of each species. The SEC yielded complete protein recovery (no protein loss) when 
compared with appropriate controls. 
4. RESULTS AND DISCUSSION 
4.1 Examination of Breakout force and Expulsion force profile for variations 
within batches and between batches 
Staked needle syringes 
Five batches of concentration 60 µg/ml and three batches of 
concentration 120 µg/ml were tested. Thirty samples were tested from each batch. To 
study the within batch variability, the thirty samples were obtained as ten beginning, 
ten middle and ten end samples. 
Luer-slip needle syringes 
Five batches of concentration 60 µg/ml were tested. Thirty samples 
were tested from three batches and five samples were tested from two batches. 
Substantial intra-batch (i.e. within the beginning, middle and end 
syringes) and inter-batch variability were seen in the expulsion force profiles of the 
syringes tested. Some examples are shown in figure 2 and 3. It was believed that the 
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variability could be due to the effect of age of silicone oil or uneven amounts of 
silicone oil. The batches tested were of ages from 8 months to 35 months. It was 
assumed that the silicone oil might have lost its lubricant action with age and hence 
caused the inter-batch variations. The breakout force for all the batches tested along 
with their ages are tabulated in table 1 and graphed in figure 4. Though there were 
substantial differences in the breakout force from batch-batch, no consistent increase 
in the breakout force with increase in age of the batch was seen. Thus the data was 
inconclusive in determining the effect of age of silicone oil on the breakout force of a 
synnge. 
It is noteworthy that the batches tested did not show a smooth expulsion 
force profile as shown in figure 1. From figure 5, it can be seen that the Fmax at 15 
mm extension was greater than the Fmax at 10 mm extension for all the batches 
tested, indicating that more force was required to expel the drug as it neared the 
needle end of the syringe. 
4.2 Effect of viscosity of silicone oil 
Silicone oils used as lubricants have a degree of polymerization (n = 400 
to 1200) such that their kinematic viscosities are nominally between 1000 cSt and 
30,000 cSt (2). Vetter Pharma is the contract manufacturer for Biogen Inc., for pre-
filled syringe filling. Two types of silicone oils (the 1000 cSt and 12,500 cSt silicone 
oils) have been used by Vetter Pharma to siliconize the syringes. An in-house testing 
by Vetter Pharma was performed to analyze the possibilities of the current 
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siliconization process with regard to the oil quantity and plunger forces . The tests 
showed that the low viscosity 1000 cSt oil was more evenly distributed within the 
syringes in comparison to 12,500 cSt silicone oil. Batches produced with 1000 cSt 
oil delivered acceptable and substantially lower plunger forces than the 12,500 cSt 
oil batches. Moreover the expulsion force profiles of the 12,500 cSt oil batches were 
not smooth. They showed an increase of forces towards the right side of the force 
diagram similar to that seen in the batches tested previously (figures 2, 3). This was 
explained by less silicone oil at the needle end of the syringe compared to the upper 
end, due to a striping method used by Vetter Pharma to siliconize the syringes. 
The syringes used to study the intra-batch and inter-batch variability 
were siliconized by Vetter siliconization method. Testing was also performed on 
development syringes which were siliconized using the BD (Becton Dickinson) 
siliconization method. Characteristic differences between the two types of syringes 
are given in Table 2. A comparison of the expulsion force profile of development 
syringes and Vetter processed syringes is shown in figure 6. The BD siliconized 
syringes had break out force ranging from 3-5 N in comparison to 5-10 N in case of 
Vetter siliconized syringes. Increase of force towards the right side of the force 
diagram as seen with the Vetter processed syringes were not seen with the BD 
siliconized syringes. The obtained data thus correlated with the findings by Vetter. 
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A vonex® (Interferon beta-1 a) should be stored at 2-8°C. However, if 
refrigeration is not available, Avonex® can be stored at 25°C for up to 30 days (3). 
The effect of accelerated storage temperature on the expulsion force profiles was 
studied. Two batches were tested at temperatures, 2-8°C and 30°C (60% RH) for 6 
hrs. It was seen that the breakout force of the syringes did not show any substantial 
change with the increase in temperature (figure 7). 
4.4 Effect of surfactant 
Proteins drugs like Liquid A vonex® are susceptible to aggregation and 
precipitation when subjected to high forces. It is generally accepted that the pathway 
leading to aggregate formation is related to the conformational changes a protein 
molecule undergoes when exposed to an interface (4). Protective excipients such as 
non-ionic surfactants are usually added to solutions of therapeutic proteins in order 
to maintain adequate shelf life and protect patients against possible adverse effects of 
protein aggregation and degradation (5). The protective excipient present in Liquid 
Avonex® is the non-ionic surfactant, tween 20. The mechanism by which a 
surfactant acts to protect the protein is not clear, although several possibilities exist. 
One such mechanism is competition with the protein for adsorption on various 
interfaces, such as the air/solution interface or vial/solution interface thus protecting 
against denaturation and aggregation at these interfaces (5). 
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It was believed that the presence of surfactant would reduce the breakout 
force of the pre-filled syringes. Four formulations were prepared: 4.8A Buffer (73.06 
mN/m), 4.8A Buffer with 0.005% Tween (49.81 mN/m), IFN-beta-la with 4.8A 
Buffer (52.59 mN/m), IFN-beta-la with 4.8A Buffer and 0.005% Tween 20 (43.03 
mN/m). Kruss Tensiometer was used to determine their surface tension. The four 
formulations were filled in to luer-slip syringes, siliconized by BD siliconization 
method and were subjected to compressive testing by Instron. Unlike the luer-slip 
batches previously tested, the expulsion force profiles of these syringes were smooth 
(no increase of forces towards the right side of the force diagram, Figure 8). This was 
believed to be due to the BD siliconization process, which used 1000 cSt silicone oil 
for the barrel and plunger. The breakout force had an average of 4.01 ± 0.38 N for 
the four formulations . Hence it can be confirmed that 1000 cSt silicone oil was more 
evenly distributed and gave better ease of injectability than the 12,500 cSt silicone 
oil. There were no substantial differences in the breakout force for the four 
formulations (Table 3). Thus presence of surfactant did not affect the expulsion force 
profile of the pre-filled syringes. 
4.5 Effect of expulsion speed 
The characterization of the structure of a protein drug is complex 
because of the presence of primary, secondary, tertiary, and quaternary structures (6). 
The complex hierarchy of the protein may be disrupted by multiple possible 
destabilizing mechanisms (7). When a protein drug is given as an intramuscular 
injection using an autoinjector, there are possibilities that the force of expulsion 
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might have a significant effect on the integrity of the protein. The effect of high 
speed on the expulsion force profile of Liquid A vonex® was studied. Liquid 
Avonex® formulations were expelled at a speed of 500 mm/min (maximum speed 
limit of Instron). The extension was set to 20 mm, load to 0.15 N and time to 150 
msec. The structural integrity of the protein was studied by subjecting the expelled 
liquid to size exclusion chromatography (SEC). The samples were divided into two 
groups: Syringe samples that were expelled through syringes and Non synnge 
samples (control samples) that were formulated and directly subjected to size 
exclusion chromatographic analysis. The syringe samples were in turn expelled in 
two ways: expulsion through Instron and manual expulsion using high force. The 
percent total aggregate of the test samples were found to be within the specifications 
when compared to the control (Table 4). The integrity of the protein was thus found 
to be unaffected by the speed of expulsion. 
4.6 Needle Penetration Studies 
With regard to the needle, pain associated with IM injections can be 
considered to be related to three factors: needle penetration of the skin, penetration 
of the needle through the skin and muscle, and pulling/tearing of the skin and/or 
muscle tissues as the needle moves non-linearly with some curvature in its 
penetration path (8). Little attention had been given in the literature regarding the 
movement patterns of an injection and bow movement patterns might be associated 
with pain (9). It is believed that an optimal injection should have relatively linear 
motion of the needle during penetration (8). Factors affecting the linear motion are 
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the size, shape and sharpness of the needle. Previous studies have shown that the 
geometry of a needle is an important factor affecting the ease of tissue penetration 
(10, 11). Sharpness of a needle has been evaluated in terms of the maximum force 
required to penetrate synthetic membranes. However these studies did not examine 
the load-displacement curve of the needle penetration (12). 
An Investigation Report conducted on a Clinical Trial summarized 
approximately thirty to forty complaints regarding duller sharps and increased pain 
upon injection from six clinical sites that used Liquid A vonex® staked needles. It 
was believed that during the processing, siliconizing and shielding of staked needles, 
the tips and shafts become dull and in some case defective. To further confirm the 
assumption, the penetration force profile of luer-slip and staked needles were studied 
by penetrating the needles in to an IMIP. The IMIP is a multi-layered soft tissue 
block used for practicing tissue injection techniques. 
The penetration studies indicated that a slightly greater Fmax was 
required to penetrate the IMIP for staked needle (2.3 ± 0.3 N) in comparison to the 
luerslip (1.7 ± 0.2 N). The penetration profile for the staked needle appeared skewed 
compared to the luerslip (figure 9). The data suggested that a greater resistance 
occurred with the staked needles during penetration into the IMIP, which resulted in 
non-linear motion of the needles. This is believed to be due to the dull sharps of the 
staked needles. Thus staked needle syringes would cause a considerable amount of 
pain when injected intramuscularly. 
29 
( 
5. CONCLUSION 
In this study Liquid A vonex® luer-slip and staked needle syringes were 
subjected to compressive testing by Instron and the effects of various factors on the 
expulsion force profile were studied. The expulsion force profiles were used to 
evaluate the ease of injectability of the syringe. The viscosity of silicone oil used for 
siliconizing the syringes was found to be a critical factor affecting the ease of 
injectability. 1000 cSt silcone oil was found to give better injectability than 12500 
cSt silicone oil. Storage temperature, presence of surfactant and expulsion speed did 
not have any major effect on the expulsion force profile. A comparative study of 
luer-slip and staked needles was done and it was seen that luer-slip needles had a 
better penetration profile. 
This study demonstrates the utility of injectability measurements for the 
development of one intramuscular protein injection, Liquid A vonex®. However, the 
results reported in this paper clearly indicate that use of the Instron is very probably 
an effective and convenient way to quantify ease of injectability for many 
parenterals. It is believed that although the data reported in this paper was derived 
from investigations of one particular injection, there is no reason to believe that this 
approach would not be applicable to many other parenteral products. 
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Figure 8. Effect of surfactant on expulsion force profile of Liquid Avonex® luer-slip 
syringes (siliconized by BD), n=lO 
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Figure 9. Needle penetration profile ofluer-slip and staked needles (n=3: 
samples having low, medium and high Fmax at 32 mm) 
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Table 1. 
Age of silicone oil of the batches tested and their force at breakout 
Age Batch Cone. Average Fmax (N) AVG SD 
(months) no. (µg/mL) Beg Mid End 
(10) (10) (10) 
8 142004 60 3.96 (5) 3.96 0.69 
8 142003 60 3.26 (5) 3.26 0.53 
16 107001 60 3.00 3.49 2.72 3.07 0.39 
19 046008 60 6.67 5.63 5.46 5.92 2.56 
22 033007 120 4.55 4.55 3.28 4.12 1.13 
23 028006 120 4.28 4.19 4.00 4.15 0.78 
23 025005 120 5.25 4.57 5.52 5.11 2.31 
24 024004 60 6.97 9.23 8.3 8.16 1.84 
24 023003 60 5.60 3.71 5.41 4.9 1.86 
24 022002 60 6.90 8.54 12.42 9.28 1.93 
24 021001 60 4.99 3.48 5.34 4.6 2.15 
32 944007 60 6.92 7.44 6.6 6.98 2.16 
35 929004 60 10.92 12.38 9.8 11.03 2.52 
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Table 2. 
Differences between the Development syringes & Vetter processed syringes 
Parameters Development Syringes Vetter Processed Syringes 
Siliconization BD Siliconization Vetter Siliconization 
Viscosity of silicone oil 1000 cSt 1000 cSt 
used for plunger 
Viscosity of silicone oil 1000 cSt 12500 cSt 
used for barrel 
Nature Hypak SCF syringes Bulk Syringes 
Method Spraying method Striping method 
Sterilization process Gamma radiation Autoclaving 
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Table 3. 
Force at breakout for the four formulations 
S.No. Buffer Buffer/Tween IFN/Buffer IFN/Tween 
/Buffer 
1. 4.56 4.44 3.85 3.86 
2. 4.36 4.39 4.06 3.41 
3. 4.24 4.02 4.09 4.21 
4. 4.35 3.73 3.71 4.15 
5. 4.26 3.63 4.37 4.50 
6. 2.67 3.86 3.89 3.61 
7. 3.36 3.61 3.74 3.89 
8. 4.25 4.03 3.77 4.06 
9. 4.66 4.39 4.03 4.07 
10. 4.25 4.39 3.64 4.08 
AVG 4.10 4.05 3.92 3.98 
SD 0.61 0.33 0.22 0.31 
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Table 4. 
Percent peak area of the samples subjected to SEC 
Percent Peak Area 
Tween 20 Sample 
Condition Monomer Dimer Agg Total Agg 
0 
Control (n=3) 99.8 0.1 0 0 
Present Instron (n=6) 99.5 0 0 0 
Manual (n=6) 99.6 0 0 0 
Control (n=3) 99.6 0.1 0.2 0.3 
Absent lnstron (n=6) 99.7 0 0.3 0.2 
Manual (n=6) 99.6 0.1 0.2 0.2 
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SUMMARY 
1. A vonex (Interferon beta-1 a) is a protein drug used for the treatment of 
relapsing forms of Multiple Sclerosis, and is administered intramuscularly 
once in a week. Intramuscular injections are a common yet complex 
technique used to deliver the medication deep into the large muscles of the 
body. Several complications have been reported following IM injections, of 
which pain at the injection site is the most common. 
2. Though factors such as site of injection, volume, concentration and nature of 
the drug may affect the reception of pain, one factor which has not apparently 
been given any attention in the published literature is the ease of injectability 
of the syringe, which is the amount of force required to expel the drug from 
the syringe. This factor can be expected to have a substantial effect on the 
discomfort experienced by patients and on the completeness of the injection. 
3. A comprehensive review of the published literature failed to reveal any 
publications dealing with the formulation of intramuscular injections with 
particular reference to factors which may affect the ease of injectability. 
Hence there is a need for some objective, quantitative method for measuring 
the ease of injectability such as may be provided by use of the Instron Series 
5500. The Instron Series 5500 has been used for several purposes in several 
fields; however no studies report the use of Instron to study the ease of 
injectability of a syringe. 
4. The potential of Instron type equipment for the quantification of ease of 
injectability of syringes has been evaluated. Compressive studies have been 
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performed on Liquid Avonex® pre-filled luer-slip and staked needle syringes 
using the Instron series 5500. The ease of injectability of the syringes was 
quantified by studying the various factors affecting the expulsion force 
profile (breakout force). 
5. Substantial inter-batch and intra-batch variations were seen in the expulsion 
force profile, which were due to the improper distribution of silicone oil 
during siliconization. 
6. The viscosity of silicone oil and the method of siliconization were found to 
be critical factors defining the expulsion force profile. The low viscosity 
1000 cSt oil was more evenly distributed within the syringes and delivered 
acceptable and substantially lower breakout forces than the 12,500 cSt oil. 
The increase of forces towards the end of the syringe as seen with the 12,500 
cSt oil was not seen with the 1000 cSt oil. Thus 1000 cSt oil gave better ease 
of injectability than the 12,500 cSt silicone oil. 
7. The presence of surfactant tween 20 in the formulation did not contribute to a 
reduction in breakout force of the syringes. 
8. Increasing the storage temperature from 2-8° C to 30° C did not have any 
substantial effect on the breakout force of the syringes. 
9. Increasing the expulsion speed from 25 mm/min to 500 mm/min (maximum 
speed limit of Instron) did not increase the percent total aggregate of 
Interferon beta-1 a. Thus the integrity of the protein was unaffected by the 
speed of expulsion. 
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10. Needle insertion is a very common invasive procedure, but little study has 
been done to study how pain is related to the mechanical properties of the 
needle insertion and how pain from the procedure can be minimized. 
11 . Needle penetration studies were conducted using the Instron to examine the 
injection profiles of staked and non-staked needles into a model 
intramuscular injection pad. The maximum force required to penetrate the 
muscle and the penetration profile of the needle into the muscle were 
recorded. The results showed that non-staked needles need lesser penetration 
force and show linear penetration profile in comparison to staked needles and 
thus cause less pain on injection. 
12. The billion-dollar biotechnology market is driving the demand for improved 
protein and peptide drug delivery products. A majority of these compounds 
have high molecular weights and solubility and stability issues that prevent 
them from being delivered via any other route other than the parenteral route. 
Hence a clear need remains for injectability studies on parenterals to be able 
to deliver the drug efficiently. 
13. It is believed that although the data reported in this paper was derived from 
investigations of one particular injection, there is no reason to believe that 
this approach would not be applicable to many other parenteral products. 
14. A variety of devices such as autoinjectors have been developed to ease the 
self-administration of injections. Injectability studies play a significant role 
for injections via autoinjectors in which the improper delivery of the drug 
might not be known to the patients. 
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( SUGGESTIONS FOR FUTURE WORK 
Some suggestions for future work which the author of the thesis was not able to 
perform due to time constrains are as follows: 
1. Of the various differences present between the development syringes and 
the vetter processed syringes, the method used to apply the silicone oil is 
a notable one. The former were siliconized using spraying method, 
whereas the latter were siliconized using striping method. Detailed 
studies of the effect of the method of siliconization on the breakout force 
of the syringe can be carried out. 
2. In-vitro needle penetration studies were carried out usmg the model 
intramuscular injection pad and it was found that luer-slip needles needed 
less force for penetrating the deep muscles and hence would cause less 
pain on injection. It may well be desirable to perform in-vivo tests (with 
approval from Institutional Review Board) with luer-slip and staked 
needles and record the pain produced on a pain measuring scale to 
confirm the in-vitro study. 
3. It may also be desirable to conduct long-term stability studies and 
evaluate the percentage aggregates of Interferon beta-la and the ease of 
injectability of the pre-filled syringes to study the effect of long-term 
storage. 
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Series 5500 System Overview 
SECTION III 
APPENDIX A 
The major components of the Instron Series 5500 system are the load 
frame, control panel and the merlin windows-based software. The control panel 
provides instant access to test functions such as start and stop, balance load, reset 
gauge and jog. The Merlin screen consists of several icons to perfom1 several 
functions. Few examples are the load frame icon which enables to load frame after a 
frame limit is tripped, extension icon to set the maximum and minimum limits, load 
cell icon to calibrate the load cell. 
The Test Control icon is the main control panel for developing a test method. It 
consists of the following test control features: 
• Motion - The Motion window is mainly used to set the speed, i.e. the rate at 
which the crosshead moves during the test. 
• Events- This window is used to enable the channel events at set values and to 
select a resulting action to occur when the event is tripped. For example, we 
might want to run a test to a specific extension (channel) limit of 4 inches, and 
when the extension reaches 4 inches, we might want to stop (action) the test. 
• Data- The Data window allows to select automatic or manual data capturing. 
Automatic data capture sets up two data channels with preset intervals to acquire 
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data. The first channel is the time with a 1 second interval. The second channel is 
load with an interval of 0.1 % of the full scale of the installed load cell. Manual 
data capture enables to select three data channels. 
Other icons are the Sample icon which is used to set parameters like the sample 
name, number of specimens etc. The Results icon allows the user to setup result 
tables. The Graph icon is used to perform the graphing functions. 
Control panel 
Figure 1. Schematic diagram of the Instron Series 5500 
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Instron Parameters/ Measurements 
The three main parameters to run a manual test method using the Instron 
5500 series are the Motion (speed) and Data (time and load). 
1. Speed: The speed is the rate at which the crosshead moves during a test. Liquid 
Avonex® pre-filled syringe samples were dispensed at four different speeds: 5, 10, 
25 and 50 mm/min and the expulsion profiles were studied. The Load was set to -30 
N and the Extension to -20 mm. The Data parameters (time and load) were set to 50 
msec and 0.15 N. The Load, Extension and Data parameters were set according to 
Biogen, Inc. 's internal document. From the four speeds tested the 25 mm/min speed 
was found to give the least amount of noise in the expulsion force profile (figure 1). 
Hence 25 mm/min speed was chosen for further studies with Liquid A vonex®. 
2. Data (Time): The Time parameter denotes the time of the test run. The data points 
will be taken according to the time interval that is set. The basic principle of setting 
the parameters is that one parameter is set constant and the others are varied. Then 
based on the nature of the expulsion profile (i.e. the amount of noise produced and 
number of data points generated), the parameters are chosen. A speed of 25 mm/min 
with a time of 50 msec gave a good expulsion profile. However with time set to 50 
msec, the amount of data points collected was too large that it generated small 
amounts of noise in the expulsion profile. Hence Liquid Avonex® was subjected to 
other time points like 25, 50, 75, 100, 150 msec. It was found that the 25 mm/min 
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speed gave a better expulsion profile with a time interval of 150 msec in comparison 
to 50 msec. 
3. Data (Load): The third parameter to be set was the load for data capture. A load 
of 0.15 N was initially used for the speed test and the time test. However, Liquid 
Avonex® was also subjected to 0.15, 0.25, 0.5 , 0.75 N load levels . The expulsion 
profiles were studied and the 0.15 N load was considered suitable to develop the 
manual test method for the Instron 5500 series. 
53 
Speedtest 
70 
60 
- 50 c: 
ca 
-
"' g 40 
(,) 50 mm/min 
+ 
-
Vl 
z 
+:-. I - 30 'O ca 25 mm/min 
0 
...J 20 10 mm/min 
10 5 mm/min 
0 I ~~------------i~~ -----~-T~~~~~-.~~~~~---,r-~~~~~.-~~~~~.-~~~~~-.--~~~~~-.--~~~~~, 
0 2 4 6 8 10 12 14 16 18 20 
Extension (mm) 
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APPENDIXB 
Appendix B contains 
1. Expulsion force profiles of Liquid Avonex® staked (Figure 1-8) and luer-
slip (Figure 9-13) syringes tested to study the within batch and batch-batch 
variability. 
2. Force at breakout for the syringes tested to study the within batch and 
batch-batch variability (Table 1 and 2). 
3. Force at breakout for the syringes tested to study the effect of storage 
temperature (Table 3). 
4. Expulsion force profile of development syringes (Figure 14 ). 
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Figure 2. Expulsion force profile of Liquid Avonex® staked needle 
syringes, Batch # 022002, n= 10 
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Figure 3. Expulsion force profile of Liquid A vonex® staked needle 
syringes, Batch # 023003, n=IO 
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Figure 4. Expulsion force profile of Liquid Avonex® staked needle 
syringes, Batch# 024004, n=lO 
61 
( Batch # 046008 
Beginning 
20 
z 15 
~ 
"O 10 co 
0 
..J 5 
0 
0 5 10 15 20 
Extension (mm) 
Middle 
20 
z 
15 
"O 10 
co 
0 
..J 5 
0 
0 5 10 15 20 
Extension (mm) 
End 
20 
z 15 
"O 10 
co 
..,,/. rJ 0 .......... 
..J 5 
0 -
0 5 10 15 20 
Extension (mm) 
Figure 5. Expulsion force profile of Liquid Avonex® staked needle 
syringes, Batch# 046008, n=lO 
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Figure 6. Expulsion force profile of Liquid Avonex® staked needle 
syringes, Batch# 025005, n=lO 
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Figure 7. Expulsion force profile of Liquid Avonex® staked needle 
syringes, Batch # 028006, n= 10 
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O'I 
,.-
Batch Force at breakout 
No. 1 2 3 4 5 6 7 8 9 
021001 Be__g_ 3.32 3.22 7.52 7.03 2.65 2.96 7.46 4.3 3.39 
Mid 4.77 2.83 3.56 5.19 2.98 2.91 5.33 2.59 1.94 
End 3.24 3.43 8.64 3.23 8.48 5.49 5.49 3.05 1.56 
022002 Be_g_ 5.6 7.86 10.21 10.22 7.74 5.72 5.57 4.54 3.56 
Mid 7.6 5.97 7.64 10.58 8.80 10.31 8.10 9.58 9.14 
End 15.02 14.19 13.5 11.52 10.33 13.07 8.76 14.10 13.75 
023003 Be__g_ 5.47 7.00 3.28 6.71 4.56 4.9 8.86 4.09 7.38 
Mid 3.44 3.14 2.75 7.19 2.83 3.47 3.15 4.02 3.19 
End 4.04 3.14 10.75 3.67 4.19 7.45 5.18 3.03 4.89 
024004 Be_g_ 8.50 8.38 7.80 5.24 7.45 2.99 7.90 7.90 4.86 
Mid 9.54 9.86 10.58 7.99 8.72 10.61 6.05 10.62 10.17 
End 9.28 8.46 11.48 10.75 7.51 3.90 7.95 6.54 8.47 
046008 Be_g_ 8.3 3.36 9.32 9.13 6.31 7.18 6.35 7.4 5.17 
Mid 3.85 3.32 4.95 9.68 7.35 7.01 10.1 3.29 4.11 
End 3.59 3.88 3.68 11.38 3.20 7.21 9.92 3.86 3.76 
025005 Be_g_ 4.02 3.18 3.45 4.55 4.00 3.34 9.21 7.27 3.46 
Mid 3.48 3.91 4.01 4.10 3.43 6.43 3.79 7.50 5.65 
End 3.13 6.34 5.16 3.44 8.82 4.34 3.06 4.19 4.58 
028006 Be_g_ 5.91 4.05 3.56 5.15 3.49 5.05 4.25 3.7 3.77 
Mid 4.22 4.41 2.56 3.05 6.93 3.73 4.72 3.47 4.17 
End 3.90 4.48 3.74 3.79 4.17 3.30 4.37 3.94 4.12 
033007 Be_g_ 4.00 3.15 3.65 5.05 4.23 3.65 9.20 7.54 3.50 
Mid 4.13 5.01 6.31 4.25 4.47 3.53 3.41 4.30 7.01 
End 2.91 2.85 5.55 2.62 3.36 3.33 3.39 3.50 2.15 
Table 1. Force at breakout for Liquid Avonex® pre-filled staked needle syringes. 
AVG SD AVG 
10 (10) (10) (30) 
8.07 4.99 2.23 4.60 
2.64 3.48 1.20 
10.82 5.34 3.03 
8.00 6.90 2.27 9.29 
7.72 8.54 1.41 
10.10 12.42 2.11 
3.77 5.60 1.81 4.91 
3.87 3.71 1.29 
7.75 5.41 2.49 
8.64 6.97 1.92 8.17 
8.18 9.23 1.49 
8.66 8.30 2.12 
4.22 6.67 2.00 5.92 
2.66 5.63 2.72 
4.11 5.46 2.97 
10.02 5.25 2.59 5.11 
3.41 4.57 1.44 
12.17 5.52 2.91 
3.91 4.28 0.81 4.16 
4.67 4.19 1.19 
4.18 4.00 0.34 
9.75 5.37 2.49 4.40 
3.10 4.55 1. 
3.13 3.28 0.90 
( Luer-slip needle syringes, 60 µg/ml 
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Figure 9. Expulsion force profile of Liquid Avonex® luer-slip syringes, 
Batch # 929004, n= 10 
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Figure 10. Expulsion force profile of Liquid Avonex® luer-slip 
syringes, Batch # 944007, n= 10 
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Figure 11. Expulsion force profile of Liquid A vonex® luer-slip 
syringes, Batch # 107001, n= 10 
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Figure 12. Expulsion force profile of Liquid Avonex® luer-slip 
syringes, Batch# 142003, n=5 
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Figure 13. Expulsion force profile of Liquid Avonex® luer-slip 
syringes, Batch # 142004, n=5 
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-....., 
Batch Force at breakout AVG SD AVG 
No. 1 2 3 4 5 6 7 8 9 10 (10) (10) i_30l 
929004 Be_g_ 11.33 11.92 7.06 14.94 11.79 10.35 13.09 12.86 10.71 5.1 10.92 0.15 
Mid 9.13 10.49 13.46 13.48 11.64 15.8 12.32 12.04 13.83 11.61 12.38 1.87 11.03 
End 10.63 13.24 8.24 7.43 10.3 10.63 11.91 10.54 4.04 11.03 9.80 2.61 
944007 Be_g_ 7.14 6.29 6.63 7.83 4.13 6.04 8.66 7.16 8.98 6.30 6.92 1.40 
Mid 6.86 8.65 13.85 6.79 7.55 5.99 4.96 7.37 7.17 5.21 7.44 2.51 6.98 
End 9.88 6.8 10.02 4.43 10.7 5.54 4.75 4.35 4.78 4.72 6.60 2.59 
107001 Be_g_ 3.48 2.65 2.35 4.88 3.07 2.81 3.43 2.96 2.32 2.06 3.00 0.81 
Mid 2.95 2.6 3.3 4.00 2.94 4.62 3.56 4.09 3.85 2.99 3.49 0.64 3.07 
End 2.41 2.01 2.6 3.02 2.40 2.96 2.83 3.5 2.58 2.95 2.72 0.42 
-...) 
142003 3.01 3.45 3.74 3.64 2.46 - - - - - 3.26i_5l 0.53_i5l 3.26i_5l 
142004 4.62 4.71 3.87 3.36 3.22 - - - - - 3.96i_5l 0.69_i5l 3.96_(_51 
Table 2. Force at breakout for Liquid Avonex® pre-filled luer-slip syringes. 
-.....) 
N 
Batch Temperature Time Breakout force _ilil AVG 
no. (hrs) 1 2 3 4 5 
1 8.15 6.89 7.36 6.01 6.58 7.00 
2-8°C 2 10.9 10.08 8.65 8.27 6.03 8.79 
3 9.41 7.48 6.62 6.99 6.29 7.36 
024004 6 8.26 7.4 6.62 6.99 6.29 7.11 
1 8.91 8.66 7.65 6.01 5.24 7.29 
30°C 2 8.85 8.44 8.2 6.93 7.78 8.04 
3 10.96 8.98 8.3 6.33 5.87 8.09 
6 8.57 7.71 7.2 6.21 5.27 6.99 
1 6.71 4.22 4.23 3.68 4.22 4.61 
2-8°C 2 6.29 3.82 3.67 3.83 2.92 4.11 
3 3.85 3.47 3.17 3.05 2.84 3.28 
028006 6 6.65 3.53 3.57 3.25 3.38 4.08 
1 4.7 4.37 3.69 3.36 4.54 4.13 
30°C 2 6.24 3.33 3.5 3.48 3.03 3.92 
3 3.86 3.54 3.49 3.24 2.99 3.42 
6 4.59 4.01 3.83 3.13 3.86 3.88 
Table 3. Force at breakout for Liquid Avonex® pre-filled staked needle syringes, batch# 024004 and 028006 
stored at two temperatures 2-8°C and 30°C. 
Expulsion force profile of development syringes 
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Figure 14. Expulsion force profile of development syringes, 
Batch # 4978-18, n=lO 
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1. Introduction 
Within the scope of a Vetter intemaJ project regarding the improvement of the existing siliconisation 
process (wipe down siliconisation}, tests with different silicon oil viscosities have been performed. 
During these tests, Dow Coming DC 360 1 OOOcSt and Dow Coming DC 360 12500cSt silicone oils 
have been used. Both viscosities comply to the specifications of the European Pharmacopoea and 
the USP/NF. 
In order to compare both silicone oil viscosities the tests have been carried out under identical 
production conditions (using the same machine and in the same production area) and with the same 
material (using the same syringe batch). The silicon pumps have been set to the same output in 
silicone oil. 
·For the evaluation of the tests the plunger forces have been measured and the amount of silicon oil 
has been determined. 
2. Testresults 
2.1 Material and Methods 
The plunger forces have been determined according to Vetter work instruction W-A 08 with an 
electronic force measuring device. The limits for the forces are: Fmax single value S20 N, 
Fmax mean vaiue ~15 N for all measured values. 
The determination of silicone oil content was done according to Vetter work instruction T-GB11 S02 by 
using FTIR-spectroscopy. The limits for the contents are described in the Vetter form QCCA 162-8, 
and are max. 2,4 mg I syringe for 1 ml long syringes. 
Material: For all tests the same syringe material was used, i. e., for the comparison of the different 
dosing quantities and types of silicone oil, materials from the same batch have been utilized. The 
determination of plunger forces has been performed using washed, siliconized, and sterilized 
stoppers 4106150 and 4023/50 and syringe barrels of the same batch. The dosing cycles 
. . 
corresponded have been set to deliver 1,0 mg, 0.6 mg, 0.3 mg of silicone oil. 
2.2 Reduction of Silicone Oil Amount 
The tests were performed to analyze the possibilities of the current siliconis.ation process with regards 
to the oil quantity and plunger lorces. During the tests, different dosing quantities (cycle times of the 
oil pumps} and different types of silicone oil (1000 cSt, and 12500 cSt) were used. 
The aim of the study was to reduce the amount of silicone oil inside the syringe barrel as far as 
possible. The amount of oil in the syringe barrels and the plunger forces have been determined. 
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2.3 Further tests planned 
The distribution of the silicone oil over the different sections of the inner surface of the syringe will be 
determined. The range of the total amount of silicone oil in the syringe with fingerrest and without 
fingerrest will be determined. 
2.4. Results 
Siiicone oil 1000 est 
The plunger forces have been acceptable, even when the lowest dosing quantity was used (about 
0.43 mg per syringe). 
Silicone oil 12500 cSt: 
Only the highest dosing quantity (about 0.89 mg per syringe) ensured plunger forces within the 
acceptable range. 
During all tests, the Flurotec stoppers 402:Y50 showed higher plunger forces than stoppers 4106/50. 
See Appendix 1, Gliding Forces 
For one customer diluent product a change from 12500cSt to 1 OOOcSt silicone oil was successfully 
implemented. The evaluation of this change was done by measuring the plunger forces on pulling the 
stoppers back (measurements of 200 different syringes per batch). 
Batches produced with 1 OOOcSt oil delivered in every case acceptable plunger forces. The achieved 
plunger forces have been significantly lower than with 12500cSt oil. 
See Appendix 2, Dia~ram Pulling Forces 
3. Conclusion I Discussion 
Only by using silicone oil 1000 cSt a reduction of silicone oil quantities can be achieved ensuring 
acceptable plunger forces. 
Plunger forces for pushing the stopper, and even for pulling the stopper have been improved by using 
1 OOOcSt instead of 12500cSt silicone oil, without having to Increase the silicone oil amount within the 
syringe. The increase of the forces to the right side of t~e force diagram (Appendix 1, the right side of 
the diagram corresponds to the needle-side of the syringe) can be explained by less silicone oil at this 
location compared to the fingerrest side. This effect is more pronounced with 12500cSt treated 
syringes. Silicon distribution data (data not shown) confirm this finding in that 1 OOOcSt silicone oil can 
be more evenly distributed than 12500cSt silicone oil. \oa.> c. <\l. ~<-"-'- "'\C.••;..,_ 
- 1.,._ ""'""~ ,.___ .,a...,~;-l..J.J -11...,. 
... fl'" ....... qJ... ..... J.....c..u......_ o...:: • 
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4. Approval 
- 2J:Ot.OZ. 
,-
Verified: Dr(. G ssmann/Productlon [Date t Signature] 
~ {,At <S C/-'!.vl 
Approved: J.}e1 Boca/Quality Assurance [Date I Signature] 
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Appendix 1, 1000 cSt Silcone Oil 
Each diagram includes 50 force measurements 
(measurements of 50 different syringes) 
Syringe batch: WE 0003217--01 
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Appendix 1, 12.500 cSt Sllcone Oil 
Each diagram Includes 50 force measurements 
(measurements of 50 different syringes) 
Syringe batch: WE 0003217-01 
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Appendix2 
At each batch there were done 200 force measurements (measurements of 200 different syringes per batch) 
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APPENDIXD 
Appendix D contains 
1. Comparison of needle penetration profile graphs of Liquid Avon ex® luer-slip 
and staked needles (figure 1-3) 
2. The Fmax at 32 mm extension for the luer-slip and staked needles (Table 1 ). 
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Figure 1. Comparison of needle penetration profiles of Liquid A vonex® 
luer-slip and staked needles, n=lO, Set # 1. 
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Figure 2. Comparison of needle penetration profiles of Liquid Avonex® luer-slip 
and staked needles, n=lO, Set # 2. 
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Figure 3. Comparison of needle penetration profiles of Liquid Avonex® 
luer-slip and staked needles, n=lO, Set# 3 
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Syringe number Fmax (32 mm extension) 
Luer-sl!Q_ needles Staked needles 
1 2.2736 2.0998 
2 1.8971 2.4011 
3 1.7860 2.4904 
4 1.8209 2.2158 
5 1.7233 1.9771 
6 1.6399 2.6931 
7 1.4493 2.1881 
8 1.7001 1.9877 
9 1.7704 2.5161 
10 1.7545 2.0784 
11 1.7594 1.9334 
12 1.3248 1.9979 
13 1.6225 1.6256 
14 1.5301 1.7651 
15 1.6090 1.9517 
16 1.8621 2.6236 
17 1.5861 2.0907 
18 1.7867 2.5457 
19 2.1026 2.2740 
20 1.5005 2.5050 
21 1.6884 2.6622 
22 1.6641 2.0735 
23 1.6651 2.1540 
24 1.8341 2.1723 
25 1.6848 2.5185 
26 1.6045 2.2073 
27 1.6520 2.1900 
28 1.4055 1.9967 
29 1.8741 2.0617 
30 1.6657 3.3899 
AVG 1.7079 2.2462 
SD 0.1902 0.3442 
Table 1. Fmax for luer-slip and staked needles at 32 mm extension 
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Appendix E contains 
1. Details of the size exclusion chromatography method used to quantify the 
percentage aggregates of Inteferon beta-1 a. 
2. Percent peak area of all the samples subjected to SEC (Table 1 ). 
3. Mean values of the percent peak area of the samples subjected to SEC 
(Table 2). 
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Quantification of aggregate percentage of Interferon beta-1 a was done 
usmg Size Exclusion Chromatography (SEC). The analysis was carried out 
according to the "Standard operating procedure for performing size exclusion 
chromatography on Interferon beta-1 a liquid formulation process intermediate and 
finished product" (SOP # 22d.320). 
The HPLC details are as follows: 
HPLC system Waters Alliance 2690 
Column Superdex® G-75 
Column Temperature Ambient 
Detection Wavelength: 215 nm 
Bandwidth 4nm 
Injection volume 200 µL (syringe samples and Blank) 
50 µL (Process intermediate samples 
and control) 
40 µL (resolution std) 
Flow rate 0.8mL/min 
Initial conditions 100% mobile phase 
Elution mode Isocratic 
Maximum system pressure 270 psi plus the pressure from pump 
to autosampler outlet 
Run stop time 30min 
Post time 4 min (Waters Alliance HPLC) 
90 
Injection queue: 
1. Blank-column wash 
2. Blank 
3. First Resolution Standard of Duplicate 
4. First Control of Triplicate- column conditioning 
5. Second control of triplicate 
6. First sample of Triplicate 
7. Second sample of Triplicate 
8. Blank 
9. Third Control of Triplicate 
10. Second Resolution Standard of Duplicate 
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Percent Peak Area 
ID No. Sample Monomer Dimer Aggregate % Total 
Condition (%) (%) (%) Aggregate 
7576-66-03 Control-A 99.9 0.1 - -
7576-66-03 Control-B 99.7 0.1 - -
7576-66-03 Control-C 99.9 0.1 - -
7576-66-04 Control-A 99.5 0.1 0.2 0.3 
7576-66-04 Control-B 99.7 0.1 0.2 0.3 
7576-66-04 Control-C 99.7 0.1 0.2 0.3 
7576-66-07 Manual-A 99.9 0.1 - -
7576-66-07 Manual-B 100 - - -
7576-66-07 Manual-C 99.3 0.1 - -
7576-66-07 Manual-D 99.5 - - -
7576-66-07 Manual-E 99.6 - - -
7576-66-07 Manual-F 99.5 - - -
7576-66-08 Manual-A 99.3 - 0.2 -
7576-66-08 Manual-B 99.5 0.1 0.2 0.3 
7576-66-08 Manual-C 99.8 0.1 0.2 0.3 
7576-66-08 Manual-D 99.5 0.1 0.2 0.3 
7576-66-08 Manual-E 99.8 - 0.2 0.2 
7576-66-08 Manual-F 99.7 0.1 0.2 0.3 
7576-66-07 lnstron-A 100 - - -
7576-66-07 lnstron-B 99.7 - - -
7576-66-07 lnstron-C 99.6 - - -
7576-66-07 lnstron-D 99.7 - - -
7576-66-07 lnstron-E 98.6 - - -
7576-66-07 lnstron-F 99.5 - - -
7576-66-08 lnstron-A 99.7 - 0.3 0.3 
7576-66-08 lnstron-B 99.7 - 0.3 0.3 
7576-66-08 lnstron-C 99.9 - 0.1 0.1 
7576-66-08 lnstron-D 99.7 - 0.3 0.3 
7576-66-08 lnstron-E 99.5 - 0.2 0.2 
7576-66-08 lnstron-F 99.7 - 0.3 0.3 
Table 1. Percent peak area of all the samples subjected to SEC 
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Percent Peak Area 
Tween ID No. Sample Monomer Dimer Aggregate 
20 Condition __{_%) (%) 1%) 
7576-66-03 Control _{_n=3) 99.8 0.1 -
Present 7576-66-07 Instron (n=6) 99.5 - -
7576-66-07 Manual (n=6) 99.6 - -
7576-66-04 Control _{_n=3) 99.6 0.1 0.2 
Absent 7576-66-08 Instron (n=6l 99.7 - 0.3 
7576-66-08 Manual _{_n=6) 99.6 0.1 0.2 
Table 2. Mean values of the percent peak areas of the samples subjected to SEC 
% Total 
Aggre_g_ate 
-
-
-
0.3 
0.3 
0.2 
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